GLP-1 receptor agonists have become a transformative class of medications
Regular blood glucose monitoring, liver function tests, and lipid panels provide important safety data
Applied to Retatrutide, a symmetric gap would push the real-world one-year average from the 28.7% TRIUMPH-4 number toward something closer to 21-23%
And as expected, when were talking about rare diseases, especially things like NAION, we do see some variability in the results that have been coming out, added Bert
GLP-1 medications are revolutionizing the conversation around weight loss, body confidence, and long-term wellness
For now, clinical trials with fomepizole should be the priority